Last reviewed · How we verify
Quinine plus sulfadoxine-pyrimethamine
This combination uses quinine to inhibit parasite protein synthesis and sulfadoxine-pyrimethamine to block folate metabolism in malaria parasites, providing synergistic antimalarial activity.
This combination uses quinine to inhibit parasite protein synthesis and sulfadoxine-pyrimethamine to block folate metabolism in malaria parasites, providing synergistic antimalarial activity. Used for Malaria (Plasmodium falciparum and other species), Drug-resistant malaria.
At a glance
| Generic name | Quinine plus sulfadoxine-pyrimethamine |
|---|---|
| Sponsor | Albert Schweitzer Hospital |
| Drug class | Antimalarial combination |
| Target | Plasmodium DNA/protein synthesis; dihydrofolate reductase; dihydropteroate synthase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Quinine is a cinchona alkaloid that intercalates into parasite DNA and inhibits protein synthesis, while sulfadoxine-pyrimethamine is a fixed-dose combination that inhibits sequential steps in folate synthesis (dihydropteroate synthase and dihydrofolate reductase), disrupting nucleotide synthesis in Plasmodium species. Together, these agents provide complementary mechanisms against drug-resistant malaria parasites.
Approved indications
- Malaria (Plasmodium falciparum and other species)
- Drug-resistant malaria
Common side effects
- Cinchonism (tinnitus, headache, visual disturbances)
- Gastrointestinal upset
- Hypersensitivity reactions (rash, Stevens-Johnson syndrome)
- Hemolytic anemia (in G6PD deficiency)
- Photosensitivity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: